TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02215733
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03581877
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
Study: NCT02380508
Drug: BCG SSI
Normalized name: BCG SSI
DrugBank: Bacillus calmette-guerin substrain danish 1331 live antigen (DB12386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection
Study: NCT02380508
Drug: BCG Sii
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal injection
Study: NCT02120664
Drug: Florbetapir (18F)
Normalized name: florbetapir (18F)
DrugBank: Florbetapir F-18 (DB09149)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02120664
Drug: 11C-PiB
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01699737
Drug: JTT-851
Normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01699737
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated Glimepiride tablets
Study: NCT02812992
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02812992
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00014287
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04515056
Drug: Papain 10 µg
Normalized name: Papain
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The area will be exposed to 10 µg of papain.
Study: NCT04515056
Drug: Papain 50 µg
Normalized name: Papain
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The area will be exposed to 50 µg of papain.
Study: NCT04515056
Drug: Papain 100 µg
Normalized name: papain 100 MG
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The area will be exposed to 100 µg of papain.
Study: NCT04515056
Drug: Papain 1 SPT
Normalized name: Papain
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papain will be applied by 1 SPT prick thought the skin
Study: NCT04515056
Drug: Papain 5 SPT
Normalized name: Papain
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papain will be applied by 5 SPT pricks thought the skin
Study: NCT04515056
Drug: Papain 25 SPT
Normalized name: Papain
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papain will be applied by 25 SPT pricks thought the skin
Study: NCT03923010
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
Study: NCT02470923
Drug: Nicotine replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00568698
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02895360
Drug: BAL101553 at MTD
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
Study: NCT00210522
Drug: RWJ 333369
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
Study: NCT01811940
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 100 mg bid.
Study: NCT02143141
Drug: duramorph
Normalized name: Duramorph
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
Study: NCT00583271
Drug: triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
Study: NCT03792347
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
Study: NCT01114490
Drug: anacetrapib
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet
Study: NCT00490945
Drug: VEC-162
Normalized name: B-VEC
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02324777
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
Study: NCT00415701
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
Study: NCT00415701
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single induction dose of propofol 2%; total dose 1.5 mg/kg
Study: NCT04109742
Drug: Placebo curcumin capsule
Normalized name: curcumin Oral Capsule
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to active curcumin capsules
Study: NCT02918929
Drug: EDP 305
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479089
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
Study: NCT00479089
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment.
Study: NCT03453723
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
Study: NCT03158389
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: twice daily (oral)
Study: NCT00666198
Drug: SILDENAFIL
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration.
Study: NCT02165397
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 420 mg of Ibrutinib orally.
Study: NCT02165397
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive rituximab 375 mg/m\^2 IV.
Study: NCT03430050
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone capsule
Study: NCT03158389
Drug: Idasanutlin
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally on 5 days of a 28 days cycle
Study: NCT00236184
Drug: rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study: NCT03158389
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: i.v. every 3 weeks
Study: NCT03158389
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: daily orally
Study: NCT03158389
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: weekly i.v.
Study: NCT03158389
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: orally on 21 days of a 28 days cycle
Study: NCT03016598
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
Study: NCT01113671
Drug: Vitamin E (d-alpha-tocopheryl acetate)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100% natural source d-alpha-tocopheryl acetate in a soft gel cap
Study: NCT03757078
Drug: Relief Pro cream
Normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
Study: NCT03548493
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
Study: NCT03548493
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
Study: NCT03201900
Drug: E2007
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT03903835
Drug: Enzalutamide Oral Capsule
Normalized name: enzalutamide Oral Capsule
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
Study: NCT03903835
Drug: Abiraterone Oral Tablet
Normalized name: abiraterone Oral Tablet
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study: NCT03903835
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].
Study: NCT03903835
Drug: Cabazitaxel 60 mg Solution for Injection
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study: NCT03903835
Drug: Docetaxel Injectable Solution
Normalized name: docetaxel Injectable Solution
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study: NCT03903835
Drug: Radium Chloride Ra-223
Normalized name: Radium chloride Ra-223
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study: NCT03903835
Drug: Niraparib plus Abiraterone acetate plus Prednisone
Normalized name: abiraterone acetate / niraparib Pill
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
Study: NCT03903835
Drug: Capivasertib plus Docetaxel
Normalized name: Capivasertib
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
Study: NCT03903835
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
Study: NCT03903835
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
Study: NCT01414426
Drug: vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00784745
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg morning and night for 5 days.
Study: NCT01636622
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
Study: NCT01636622
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
Study: NCT01636622
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
Study: NCT00144846
Drug: albuterol sulfate inhalation aerosol
Normalized name: Albuterol Inhalation Aerosol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00019695
Drug: alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00019695
Drug: ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00900783
Drug: valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gram, three times a day for seven days
Study: NCT00900783
Drug: FV-100
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
DrugBank: Horseradish (DB10674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg, once daily, for seven days
Study: NCT00900783
Drug: FV-100
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
DrugBank: Horseradish (DB10674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, once daily, for seven days
Study: NCT00900783
Drug: Valacyclovir placebo
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: three times a day, for seven days
Study: NCT00964457
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab 500mg per meter square every second week
Study: NCT00965120
Drug: bradykinin receptor antagonist (HOE-140)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic infusion of bradykinin receptor antagonist (HOE-140).
Study: NCT02876172
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg MDMA (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.
Study: NCT04138212
Drug: Paclitaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
Study: NCT02780505
Drug: vitamin c
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples.
Study: NCT00561899
Drug: SP, amodiaquine, piperaquine, dihdroartemisinin
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once every month during september, October and November
Study: NCT00561899
Drug: Du-Cotecxin
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
Study: NCT00005946
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00001359
Drug: Penicillin or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03922607
Drug: ABBV-157
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-157 will be administered orally as capsule
Study: NCT04044703
Drug: Vancomycin - model-based dosing regimen
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
Study: NCT02602483
Drug: Magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01423708
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of \>5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels \<5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
Study: NCT00507221
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days
Study: NCT00832000
Drug: Mexiletine
Normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg three times a day; in pill form
Study: NCT04718233
Drug: Sildenafil 25Mg Tablet
Normalized name: sildenafil 25 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
Study: NCT00507221
Drug: Praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At enrollment and 12 months: 25mg/kg X 1